Immutep Limited
IMMP
Cena:
$ 0.49
+0.01 (2.08%)
Valuace
70
Růst
10
Zdraví
100
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
IMMUTEP ACHIEVES 50% ENROLMENT IN GLOBAL TACTI-004 (KEYNOTE-F91) PHASE III TRIAL IN 1L NSCLC
06-02-2026
SYDNEY, AUSTRALIA, FEB. 06, 2026 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (“IM...
Více zde
IMMUTEP QUARTERLY ACTIVITIES REPORT Q2 FY26
29-01-2026
MEDIA RELEASE ENTERED INTO STRATEGIC COLLABORATION WITH DR. REDDY'S FOR COMMERCIALISATION OF EFTILAG...
Více zde
IMMUTEP ANNOUNCES POSITIVE UPDATE ON IMP761, A FIRST-IN-CLASS LAG-3 AGONIST ANTIBODY FOR AUTOIMMUNE DISEASES, FROM PHASE I STUDY
22-12-2025
SYDNEY, AUSTRALIA, DEC. 22, 2025 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (“IM...
Více zde
IMMUTEP ANNOUNCES STRONG OPERATIONAL PROGRESS IN GLOBAL TACTI-004 (KEYNOTE-F91) PHASE III AND ENROLMENT CONTINUES AT ROBUST PACE
16-12-2025
THE REGISTRATIONAL TACTI-004 PHASE III HAS ENROLLED 289 PATIENTS GLOBALLY, OVER 38% OF THE TRIAL'S T...
Více zde
IMMUTEP AND DR. REDDY’S ENTERS INTO STRATEGIC COLLABORATION FOR COMMERCIALISATION OF AN INNOVATIVE ONCOLOGY DRUG, EFTILAGIMOD ALFA
08-12-2025
DR. REDDY'S RECEIVES EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALISE EFTILAGIMOD ALFA IN ALL COUNTRIES...
Více zde
PRIMARY ENDPOINT MET IN EFTISARC-NEO PHASE II EVALUATING NEOADJUVANT EFTI IN SOFT TISSUE SARCOMA AND DATA PRESENTED AT ESMO CONGRESS 2025
20-10-2025
SYDNEY, AUSTRALIA, OCT. 20, 2025 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (“IM...
Více zde
IMMUTEP ANNOUNCES DATA FROM EFTISARC-NEO PHASE II EVALUATING NEOADJUVANT EFTI IN SOFT TISSUE SARCOMA ACCEPTED FOR ORAL PRESENTATION AT CTOS 2025
08-09-2025
SYDNEY, AUSTRALIA, SEPT. 08, 2025 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (...
Více zde
IMMUTEP QUARTERLY ACTIVITIES REPORT Q4 FY25
30-07-2025
MEDIA RELEASE THE PIVOTAL TACTI-004 PHASE III TRIAL IN FIRST LINE NON-SMALL CELL LUNG CANCER (1L NSC...
Více zde
IMMUTEP TO PRESENT PIVOTAL TACTI-004 TRIAL IN PROGRESS POSTER AT THE 2025 WORLD CONFERENCE ON LUNG CANCER
29-07-2025
SYDNEY, AUSTRALIA, JULY 29, 2025 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (“IM...
Více zde
IMMUTEP'S EFTI WITH RADIOTHERAPY & KEYTRUDA® (PEMBROLIZUMAB) MEETS PRIMARY ENDPOINT IN PHASE II FOR SOFT TISSUE SARCOMA
27-05-2025
SYDNEY, AUSTRALIA, MAY 27, 2025 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (“IMM...
Více zde
IMMUTEP TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
02-04-2025
SYDNEY, AUSTRALIA , APRIL 02, 2025 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (...
Více zde
IMMUTEP QUARTERLY ACTIVITIES REPORT Q2 FY25
31-01-2025
MEDIA RELEASE MARKING IMMUTEP'S TRANSITION TO A PHASE III BIOTECH, THE COMPANY'S PIVOTAL TACTI-004 T...
Více zde
IMMUTEP ANNOUNCES INITIAL SAFETY DATA FROM FIRST-IN-HUMAN PHASE I TRIAL EVALUATING IMP761
17-12-2024
SYDNEY, AUSTRALIA, DEC. 17, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) ("IMMU...
Více zde
IMMUTEP REPORTS PROMISING NEW DATA IN HEAD AND NECK CANCER AT ESMO IMMUNO-ONCOLOGY 2024
12-12-2024
SYDNEY, AUSTRALIA, DEC. 12, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) ("IMMU...
Více zde
IMMUTEP'S EFTI SHOWS EXCELLENT SURVIVAL DATA FROM INSIGHT-003 TRIAL IN NON-SMALL CELL LUNG CANCER
14-11-2024
MEDIA RELEASE MATURE DATA IN PATIENTS WITH A MINIMUM FOLLOW-UP OF 22 MONTHS (N=21) SHOWS EXCELLENT R...
Více zde
IMMUTEP QUARTERLY ACTIVITIES REPORT Q1 FY25
29-10-2024
SYDNEY, AUSTRALIA, OCT. 29, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) ("IMMU...
Více zde
IMMUTEP TO PARTICIPATE IN THE 2024 MAXIM HEALTHCARE VIRTUAL SUMMIT
10-10-2024
MEDIA RELEASE SYDNEY, AUSTRALIA, OCT. 10, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ...
Více zde
IMMUTEP'S EFTI IN COMBINATION WITH MSD'S KEYTRUDA® LEADS TO POSITIVE EFFICACY WITH FAVOURABLE SAFETY IN FIRST LINE HEAD AND NECK CANCER
16-09-2024
SYDNEY, AUSTRALIA, SEPT. 16, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (“I...
Více zde
IMMUTEP QUARTERLY ACTIVITIES REPORT Q4 FY24
31-07-2024
MEDIA RELEASE ENTERED INTO THIRD AND MOST IMPORTANT CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMEN...
Více zde
IMMUTEP REPORTS POSITIVE RESULTS IN FIRST LINE HEAD AND NECK SQUAMOUS CELL CARCINOMA PATIENTS WITH NEGATIVE PD-L1 EXPRESSION
11-07-2024
MEDIA RELEASE EFTI IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) ACHIEVED A 35.5% RESPONSE RATE IN ...
Více zde
IMMUTEP ANNOUNCES DETAILS FOR ORAL PRESENTATION AT ESMO VIRTUAL PLENARY SESSION AND WEBCAST TO DISCUSS CLINICAL RESULTS
03-07-2024
COMPANY TO HOST WEBCAST ON 12TH JULY AT 9AM AEST (7PM ET, 11 JULY) SYDNEY, AUSTRALIA, JULY 03, 2024 ...
Více zde
IMMUTEP SIGNS EXCLUSIVE LICENSE AGREEMENT WITH CARDIFF UNIVERSITY FOR NEXT GENERATION ANTI-LAG-3 MOLECULES FOR CANCER
25-06-2024
MEDIA RELEASE SYDNEY, AUSTRALIA, JUNE 25, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ...
Více zde
IMMUTEP SUCCESSFULLY COMPLETES INSTITUTIONAL PLACEMENT AND INSTITUTIONAL COMPONENT OF ENTITLEMENT OFFER
05-06-2024
SYDNEY, AUSTRALIA, JUNE 05, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED ACN 009 237 889 (ASX: IMM, NASD...
Více zde
IMMUTEP ANNOUNCES CLINICAL COLLABORATION WITH MSD TO EVALUATE EFTI IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PIVOTAL PHASE III TRIAL
02-06-2024
SYDNEY, AUSTRALIA, JUNE 03, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) (“I...
Více zde
IMMUTEP PRESENTS DATA FROM SAFETY LEAD-IN PHASE OF AIPAC-003 AT ESMO BREAST 2024
15-05-2024
MEDIA RELEASE CONFIRMED COMPLETE RESPONSE IN A PATIENT WITH METASTATIC BREAST CANCER REFRACTORY TO S...
Více zde
POSITIVE INITIAL CLINICAL DATA REPORTED FROM IMMUTEP'S EFTI COMBINED WITH RADIOTHERAPY AND CHECKPOINT INHIBITOR FROM PHASE II TRIAL IN SOFT TISSUE SARCOMA
02-05-2024
MEDIA RELEASE NOVEL TRIPLE COMBINATION OF EFTI WITH RADIOTHERAPY AND ANTI-PD-1 THERAPY IS WELL TOLER...
Více zde
IMMUTEP QUARTERLY ACTIVITIES REPORT Q3 FY24
29-04-2024
MEDIA RELEASE FIRST CLINICAL DATA FROM THE SAFETY LEAD-IN OF AIPAC-003 IN METASTATIC BREAST CANCER S...
Více zde
IMMUTEP ANNOUNCES POSITIVE PRELIMINARY TOPLINE RESULTS FROM TACTI-003 COHORT B
24-04-2024
MEDIA RELEASE DATA FROM EFTI IN COMBINATION WITH KEYTRUDA® IN FIRST LINE HEAD AND NECK SQUAMOUS CEL...
Více zde
IMMUTEP APPOINTS LEADING RESEARCH INSTITUTE TO CONDUCT FIRST-IN-HUMAN PHASE I STUDY OF IMP761
18-04-2024
MEDIA RELEASE CENTRE FOR HUMAN DRUG RESEARCH (CHDR) WILL CONDUCT PHASE I TRIAL TO EVALUATE IMP761, A...
Více zde
IMMUTEP RECEIVES POSITIVE FEEDBACK FROM THE SPANISH MEDICINES AGENCY FOR UPCOMING TACTI-004 REGISTRATIONAL TRIAL IN METASTATIC NON-SMALL CELL LUNG CANCER
17-04-2024
SYDNEY, AUSTRALIA, APRIL 17, 2024 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) ("IMM...
Více zde
Dokumenty nejsou k dispozici
